Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Director · Chief Executive Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-04-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-04-20 · Conversion · Acquired 1,386,746 · Balance 1,499,797 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Row 2 · 2026-04-20 · Conversion · Acquired 364,268 · Balance 1,864,065 F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Row 3 · 2026-04-20 · Other · Disposed 1,864,065 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. |
| Common StockSEC Table I · non-derivative | Direct | 1,940,574 |
Ending reported balance
After 2026-04-20 transaction · row 5
2 source rows · reconciled sequenceRow 4 · 2026-04-20 · Other · Acquired 1,864,065 · Balance 1,864,065 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Row 5 · 2026-04-20 · Grant · Acquired 76,509 · Balance 1,940,574 F4: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Class B Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,224,152 |
Reported balance
After 2026-04-20 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-04-20 · Conversion · Acquired 1,224,152 · Balance 1,224,152 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Class B Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2026-04-20 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-04-20 · Other · Disposed 1,224,152 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,224,152 |
Reported balance
After 2026-04-20 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-04-20 · Other · Acquired 1,224,152 · Balance 1,224,152 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 341,191 |
Reported balance
After 2026-04-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-16 · Grant · Acquired 341,191 · Balance 341,191 F5: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-04-20 · Other · Disposed 266,311 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2027-02-15 | Direct | 266,311 |
Reported balance
After 2026-04-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-04-20 · Other · Acquired 266,311 · Balance 266,311 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-04-20 · Other · Disposed 25,310 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2027-02-15 | Direct | 25,310 |
Reported balance
After 2026-04-20 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-04-20 · Other · Acquired 25,310 · Balance 25,310 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-01-17 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-04-20 · Other · Disposed 23,986 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-01-17 | Direct | 23,986 |
Reported balance
After 2026-04-20 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-04-20 · Other · Acquired 23,986 · Balance 23,986 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-04-24 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-04-20 · Other · Disposed 20,023 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-04-24 | Direct | 20,023 |
Reported balance
After 2026-04-20 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2026-04-20 · Other · Acquired 20,023 · Balance 20,023 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2034-04-16 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2026-04-20 · Other · Disposed 27,700 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2034-04-16 | Direct | 27,700 |
Reported balance
After 2026-04-20 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2026-04-20 · Other · Acquired 27,700 · Balance 27,700 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2026-04-20 · Other · Disposed 1,033,912 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 1,033,912 |
Reported balance
After 2026-04-20 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2026-04-20 · Other · Acquired 1,033,912 · Balance 1,033,912 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2026-04-20 · Other · Disposed 37,086 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2035-01-15 | Direct | 37,086 |
Reported balance
After 2026-04-20 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2026-04-20 · Other · Acquired 37,086 · Balance 37,086 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2026-04-20 · Other · Disposed 42,334 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
| Class A Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-20 · Conversion · Disposed 1,020,742 · Balance 0 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Founders Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-20 · Conversion · Disposed 366,004 · Balance 0 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-20 · Conversion · Disposed 880,802 · Balance 0 F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectBy Spouse | 0 |
Reported balance
After 2026-04-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-04-20 · Conversion · Disposed 1,224,152 · Balance 0 F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). |
| Stock Option ((Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-01-14 | Direct | 42,334 |
Reported balance
After 2026-04-20 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2026-04-20 · Other · Acquired 42,334 · Balance 42,334 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
F2: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
F4: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F5: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F6: Fully vested.
F7: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date.
F8: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
F9: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
F10: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
F11: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option ((Right to Buy) · Derivative | 42,334 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 29 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,334 Underlying: Common Stock · 42,334 shares Expires 2036-01-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 42,334 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 28 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 42,334 shares Expires 2036-01-14 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 37,086 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 27 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,086 Underlying: Common Stock · 37,086 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 37,086 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 26 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 37,086 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 1,033,912 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 25 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,033,912 Underlying: Common Stock · 1,033,912 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 1,033,912 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 24 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 1,033,912 shares Expires 2035-01-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 27,700 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 23 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,700 Underlying: Common Stock · 27,700 shares Expires 2034-04-16 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 27,700 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 22 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 27,700 shares Expires 2034-04-16 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 20,023 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 21 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,023 Underlying: Common Stock · 20,023 shares Expires 2033-04-24 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 20,023 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 20 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 20,023 shares Expires 2033-04-24 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 23,986 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 19 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,986 Underlying: Common Stock · 23,986 shares Expires 2033-01-17 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 23,986 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 18 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 23,986 shares Expires 2033-01-17 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 25,310 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 17 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,310 Underlying: Common Stock · 25,310 shares Expires 2027-02-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 25,310 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 16 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 25,310 shares Expires 2027-02-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 266,311 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 15 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,311 Underlying: Common Stock · 266,311 shares Expires 2027-02-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherStock Option (Right to Buy) · Derivative | 266,311 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 14 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 266,311 shares Expires 2027-02-15 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass A Common Stock · Derivative | 1,224,152 | $0.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 13 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Class B Common Stock · 1,224,152 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.exercise_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.expiration_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionSeries A-1 Preferred Stock · Derivative | 880,802 | $0.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 12 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 364,268 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · derivative.exercise_date: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · derivative.expiration_date: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionFounders Preferred Stock · Derivative | 366,004 | $0.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 11 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 366,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.exercise_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.expiration_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass A Common Stock · Derivative | 1,020,742 | $0.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 10 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 1,020,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.exercise_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · derivative.expiration_date: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherCommon Stock | 1,224,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 8 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,224,152 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherClass B Common Stock | 1,224,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 7 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass B Common Stock | 1,224,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 6 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,224,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantCommon Stock | 76,509 | $0.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 5 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,940,574 F4 · kind: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherCommon Stock | 1,864,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 4 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,864,065 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | OtherClass B Common Stock | 1,864,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 3 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · price: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass B Common Stock | 364,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 2 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,864,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. F2 · price: The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | ConversionClass B Common Stock | 1,386,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · nonDerivative · entry 1 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,499,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). F1 · price: The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). Read SEC document |
| April 16, 2026 Filed Apr 21, 2026 00:33 UTC | Alamar Biosciences, Inc. ALMR · Entity 1791 | GrantStock Option (Right to Buy) · Derivative | 341,191 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002126941-26-000004 · form4-04212026_120453.xml · derivative · entry 9 Luo Yuling · CIK 0002126941 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,191 Underlying: Common Stock · 341,191 shares Expires 2036-04-15 F5 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.